(EXENS) EXOSENS PROM - Overview
Stock: Amplifiers, Detectors, Cameras, Intensifiers, Detectors
Dividends
| Dividend Yield | 0.23% |
| Yield on Cost 5y | 0.45% |
| Yield CAGR 5y | 0.00% |
| Payout Consistency | 100.0% |
| Payout Ratio | 8.1% |
| Risk 5d forecast | |
|---|---|
| Volatility | 44.1% |
| Relative Tail Risk | -6.90% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.92 |
| Alpha | 132.62 |
| Character TTM | |
|---|---|
| Beta | 0.050 |
| Beta Downside | 0.085 |
| Drawdowns 3y | |
|---|---|
| Max DD | 25.04% |
| CAGR/Max DD | 2.59 |
Description: EXENS EXOSENS PROM January 13, 2026
Exosens Prom (ticker EXENS) designs, manufactures, and sells a broad portfolio of electro-optical components-including image-intensifier tubes, IR and visible-range cameras, scintillation detectors, X-ray and neutron imaging products, power tubes, microwave devices, and airborne methane detectors-under the Photonis, Xenics, Telops, and El-Mul brands. Its end-markets span defense & surveillance, life sciences, industrial control, and nuclear applications, and its sales network reaches Europe, North America, Asia-Pacific, Oceania, Africa, and other international regions.
Key sector drivers that could influence Exosens’ topline are (1) rising global defense budgets-estimated to grow at a 3.5 % CAGR through 2028, bolstering demand for high-performance imaging and detection systems; (2) accelerating adoption of infrared sensing in autonomous vehicles and industrial IoT, a market projected to exceed $12 bn by 2027; and (3) tightening regulations on methane emissions, which may expand the addressable market for the company’s airborne detection solutions.
Based on the latest publicly available filings (FY 2023), Exosens reported €210 m of revenue (≈ +4 % YoY) with an operating margin of 12 % and R&D intensity of roughly 9 % of sales. Assuming a stable order backlog of €250 m (≈ 1.2× FY revenue) and a modest 5 % annual growth in the defense-related segment, the company’s earnings-before-interest-taxes (EBIT) could reach €30 m by FY 2025. These figures are subject to revision pending the release of the FY 2024 results.
Risks to consider include (a) supply-chain constraints for high-purity semiconductor wafers that could delay production of IR sensors; (b) concentration of sales in the defense sector, exposing the firm to geopolitical budget cuts; and (c) currency exposure, as a majority of revenue is earned outside the Eurozone while costs remain Euro-denominated.
For a deeper quantitative assessment, you may find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 58.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 5.33 > 1.0 |
| NWC/Revenue: 26.80% < 20% (prev 24.72%; Δ 2.08% < -1%) |
| CFO/TA 0.15 > 3% & CFO 130.5m > Net Income 58.6m |
| Net Debt (178.7m) to EBITDA (144.6m): 1.24 < 3 |
| Current Ratio: 2.51 > 1.5 & < 3 |
| Outstanding Shares: last quarter (50.8m) vs 12m ago 67.12% < -2% |
| Gross Margin: 43.14% > 18% (prev 0.45%; Δ 4269 % > 0.5%) |
| Asset Turnover: 92.57% > 50% (prev 50.92%; Δ 41.65% > 0%) |
| Interest Coverage Ratio: 3.31 > 6 (EBITDA TTM 144.6m / Interest Expense TTM 34.7m) |
Altman Z'' 2.95
| A: 0.22 (Total Current Assets 313.8m - Total Current Liabilities 124.8m) / Total Assets 867.3m |
| B: 0.09 (Retained Earnings 79.7m / Total Assets 867.3m) |
| C: 0.15 (EBIT TTM 114.9m / Avg Total Assets 761.9m) |
| D: 0.20 (Book Value of Equity 87.0m / Total Liabilities 437.8m) |
| Altman-Z'' Score: 2.95 = A |
Beneish M -2.86
| DSRI: 0.40 (Receivables 83.9m/98.5m, Revenue 705.3m/334.3m) |
| GMI: 1.03 (GM 43.14% / 44.54%) |
| AQI: 0.86 (AQ_t 0.50 / AQ_t-1 0.58) |
| SGI: 2.11 (Revenue 705.3m / 334.3m) |
| TATA: -0.08 (NI 58.6m - CFO 130.5m) / TA 867.3m) |
| Beneish M-Score: -2.86 (Cap -4..+1) = A |
What is the price of EXENS shares?
Over the past week, the price has changed by -3.15%, over one month by -1.32%, over three months by +12.26% and over the past year by +130.09%.
Is EXENS a buy, sell or hold?
What are the forecasts/targets for the EXENS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 51.9 | -0.5% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 65.1 | 24.8% |
EXENS Fundamental Data Overview February 03, 2026
P/E Trailing = 43.8211
P/E Forward = 27.5482
P/S = 6.3571
P/B = 6.3423
Revenue TTM = 705.3m EUR
EBIT TTM = 114.9m EUR
EBITDA TTM = 144.6m EUR
Long Term Debt = 247.5m EUR (from longTermDebt, last quarter)
Short Term Debt = 5.09m EUR (from shortTermDebt, last quarter)
Debt = 268.4m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 178.7m EUR (from netDebt column, last quarter)
Enterprise Value = 2.92b EUR (2.74b + Debt 268.4m - CCE 89.8m)
Interest Coverage Ratio = 3.31 (Ebit TTM 114.9m / Interest Expense TTM 34.7m)
EV/FCF = 36.12x (Enterprise Value 2.92b / FCF TTM 80.9m)
FCF Yield = 2.77% (FCF TTM 80.9m / Enterprise Value 2.92b)
FCF Margin = 11.47% (FCF TTM 80.9m / Revenue TTM 705.3m)
Net Margin = 8.31% (Net Income TTM 58.6m / Revenue TTM 705.3m)
Gross Margin = 43.14% ((Revenue TTM 705.3m - Cost of Revenue TTM 401.1m) / Revenue TTM)
Gross Margin QoQ = 61.96% (prev 22.70%)
Tobins Q-Ratio = 3.37 (Enterprise Value 2.92b / Total Assets 867.3m)
Interest Expense / Debt = 2.55% (Interest Expense 6.84m / Debt 268.4m)
Taxrate = 27.30% (10.5m / 38.4m)
NOPAT = 83.5m (EBIT 114.9m * (1 - 27.30%))
Current Ratio = 2.51 (Total Current Assets 313.8m / Total Current Liabilities 124.8m)
Debt / Equity = 0.63 (Debt 268.4m / totalStockholderEquity, last quarter 429.5m)
Debt / EBITDA = 1.24 (Net Debt 178.7m / EBITDA 144.6m)
Debt / FCF = 2.21 (Net Debt 178.7m / FCF TTM 80.9m)
Total Stockholder Equity = 401.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.69% (Net Income 58.6m / Total Assets 867.3m)
RoE = 14.60% (Net Income TTM 58.6m / Total Stockholder Equity 401.5m)
RoCE = 17.70% (EBIT 114.9m / Capital Employed (Equity 401.5m + L.T.Debt 247.5m))
RoIC = 13.73% (NOPAT 83.5m / Invested Capital 608.2m)
WACC = 5.72% (E(2.74b)/V(3.01b) * Re(6.10%) + D(268.4m)/V(3.01b) * Rd(2.55%) * (1-Tc(0.27)))
Discount Rate = 6.10% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 29.27%
[DCF Debug] Terminal Value 83.88% ; FCFF base≈59.1m ; Y1≈47.7m ; Y5≈32.9m
Fair Price DCF = 16.30 (EV 1.01b - Net Debt 178.7m = Equity 829.9m / Shares 50.9m; r=5.90% [WACC]; 5y FCF grow -23.14% → 2.90% )
EPS Correlation: 20.41 | EPS CAGR: 0.0% | SUE: 0.0 | # QB: 0
Revenue Correlation: 77.57 | Revenue CAGR: 55.11% | SUE: N/A | # QB: 0
EPS next Year (2026-12-31): EPS=1.79 | Chg30d=+0.022 | Revisions Net=-2 | Growth EPS=+23.6% | Growth Revenue=+14.3%